-

Feinstein Institutes Researchers Evoke Sense of Touch Through Brain Implant Electrodes

MANHASSET, N.Y.--(BUSINESS WIRE)--In a first-in-human study, researchers at The Feinstein Institutes for Medical Research elicited the sense of touch through a minimally-invasive electrode brain implant. This research, published recently in Brain Stimulation, has the potential to help millions of people who live with paralysis and neuropathy.

Many illnesses and injuries, including stroke, diabetes or spinal cord injury, can produce loss of touch, which makes everyday movements difficult and takes an emotional toll on patients. Imagine not being able to feel a hot cup or the hand holding yours. Previously, through brain-computer interface (BCI) technology, researchers have been able to electrically stimulate certain (gyral) areas of the brain and restore some sensation to the hand. Through this new research, scientists have successfully shown that stimulation of harder to reach (sulcal) areas of the brain using stereoelectroencephalography (SEEG) electrodes can evoke precise sensory percepts in the fingertips.

“From buttoning our shirts to holding a loved one’s hand, our sense of touch may be taken for granted until we lose it,” said the study’s co-principal investigator, Chad Bouton, professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes. “These results show the ability to generate that sensation, even after it is lost, which may lead us to a clinical option in the future.”

Through a minimally invasive procedure led by neurosurgeon, associate professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and co-principal investigator on the study, Ashesh Mehta, MD, two patients were implanted with the SEEG electrodes in the sulci (grooves) of the brain. While providing electrical stimulation the study participants reported feelings of “tingling” or “sensation of electricity” localized to the hand and fingertips.

The Feinstein Institutes is the global scientific home of bioelectronic medicine, a field of research that combines molecular medicine, neuroscience and biomedical engineering to develop innovative therapies with the aim to treat diseases and conditions through targeted stimulation of nerves, including paralysis, arthritis, pulmonary hypertension and inflammatory bowel disease.

“Advances in artificial intelligence, brain electrodes and bioelectronic medicine hold significant promise for patients after spinal cord injury or stroke,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes. “This remarkable study indicates bioelectronic medicine and neurosurgery could restore functions previously lost in these conditions.”

To research the brain’s response, the same electrodes used for stimulation were also used to record neural signals during mechanical stimulation of the hand. This process has allowed researchers to deepen the current knowledge of neural circuitry involved in processing touch-related sensations in the human brain, noted Santosh Chandrasekaran, PhD, investigator in the study and co-lead author on the paper with colleague Stephan Bickel, MD, PhD, also an investigator in the published study.

Recent biolectronic medicine progress at the Feinstein Institutes includes a published study around the most effective dose and time of day to stimulate the vagus nerve, a major nerve in the body that controls the body’s immune response.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Matthew Libassi
631-793-5325
mlibassi@northwell.edu

The Feinstein Institutes for Medical Research


Release Versions

Contacts

Matthew Libassi
631-793-5325
mlibassi@northwell.edu

More News From The Feinstein Institutes for Medical Research

Preparing Tomorrow's Doctors: Zucker School of Medicine Leaders Share Transformative Blueprint in "Revolutionizing Medical Education"

NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--Roughly 20 years ago a new medical school turned medical education upside down by reimagining how future physicians are trained. Today, that school, the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, has become a model for other schools around the globe. Its founding physician leaders are now sharing how they closed the gap between advanced medical science and outdated educational methods in a new book, “Revolutionizing Medical Education...

Northwell Releases First-of-its-Kind Toolkit to Help Health Care Providers Implement Gun Violence Prevention Programs

NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--As health care providers across the United States are increasingly addressing gun violence as a public health crisis, a new resource will help translate years of frontline experience into action. Unveiled last month at Northwell Health’s annual Gun Violence Prevention Forum, a new digital implementation toolkit, Guiding Health Systems to Action on Firearm Injury & Violence Prevention, brings together actionable insights from hospitals and health systems...

Groundbreaking Meeting of Minds at Northwell Health’s Quantum Biology Forum Unlocks New Understanding of Life’s Fundamental Principles

MANHASSET, N.Y.--(BUSINESS WIRE)--What if healing wasn’t just about chemistry, but about the very energy and light within our bodies? This groundbreaking question guided Northwell Health’s Quantum Biology Forum, a seminal first meeting of minds held April 13-14 at United Therapeutics headquarters in Silver Spring, Maryland. Supported by Martine Rothblatt, PhD, CEO of United Therapeutics, and Northwell’s Lance B. Becker, MD, this unique event brought together over 120 pioneering scientists, indu...
Back to Newsroom